Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This is a prospective, open-label, randomized phase II clinical trial designed to compare the efficacy and toxicity of hypofractionated concurrent chemoradiotherapy versus conventional fractionated concurrent chemoradiotherapy following induction chemoimmunotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Epistemonikos ID: feff39a1828d2c4cb4bd4d84b4cf9ebd7be78918
First added on: Apr 05, 2025